Pfizer and BioNTech have also sued CureVac, asking a judge to block CureVac's infringement allegations against the companies. Acuitas has separately asked to intervene with its inventorship claims in that case in Virginia. CureVac said it is "confident that our IP complies with all applicable laws and does not breach any agreements with Acuitas" and would "vigorously defend" itself against the allegations. Acuitas said in its Monday lawsuit that it and CureVac have collaborated on mRNA-based therapeutics using its LNP technology since 2014.